Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs

Fig. 5

VPA induces expression of ErbB family members-targeting microRNAs in pancreatic cancer cells without altering mRNAs levels of EGFR, ErbB2, and ErbB3, which results in down-regulation of endogenous but not exogenous ErbB2 and ErbB3. a, b HPAF-II and MPanc96 cells untreated or treated with VPA (0.5 mmol/L) for 24 h or 48 h were harvested for total RNA preparation and subjected for analysis of mRNAs expression levels of EGFR, ErbB2, and ErbB3 with conventional (a) or quantitative RT-PCR (b). c, d HPAF-II and MPanc96 cells untreated or treated with VPA (0.5 mmol/L) for 24 h or 48 h were collected and subjected to total RNA extraction, inclusive of the small RNA fraction. The expression levels of miR-133a, miR-133b, miR-125a, miR-125b, and miR-205 were measured by qRT-PCR using TaqMan miRNA assays. All results were normalized with the internal control RNU6B. Bars, S.D. All data show the representative of three independent experiments. e HPAF-II and MPanc96 cells without or with elevated expression of either ErbB2 or ErbB3 were treated with VPA (0.5 mmol/L) for 24 h. Cells were harvested and subjected to western blot analyses with specific antibodies directed against ErbB2, ErbB3, or β-actin

Back to article page